Highlights:
- Insight from the “largest prospective study to date” of the p64 flow modulation device (phenox)
- The latest clinical data on endovascular therapy for stroke, including results from the SWIFT-DIRECT trial and the AURORA meta-analysis’ findings
- Alejandro Frangi (Leeds, UK) outlines the future role in silico studies could play alongside traditional clinical trials of flow diverters and other neurovascular devices
- Profile: Salim Hayek (Cleveland, USA)
- Neuromodulation: Nolan Williams (Stanford, USA) discusses a potential “gamechanger” for patients with treatment-resistant depression
